{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-044497","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2024-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.568322+00:00","generated_at":"2026-06-03T23:04:55.776186+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"medium","headline":"SAB Biotherapeutics completes dosing of cohort 3 for SAB-142 Phase 1 trial; no serum sickness observed","bullets":["Completed dosing of cohort 3 in Phase 1 trial of SAB-142.","No instances of serum sickness reported.","Company to issue corporate update press release on or about April 16, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-044497","json":"https://secwatch.observer/filing/0000950170-24-044497.json","markdown":"https://secwatch.observer/filing/0000950170-24-044497.md","text":"https://secwatch.observer/filing/0000950170-24-044497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024044497/0000950170-24-044497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024044497/sabs-20240412.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T23:04:55.776186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}